Recent discussions on X about Cardinal Health (CAH) have been buzzing with anticipation ahead of the company’s upcoming fourth-quarter and year-end financial results for fiscal year 2025, expected to be released on August 12. Many participants on the platform are speculating about the potential impact of these earnings, with some highlighting recent analyst upgrades as a reason for hope. The conversation reflects a keen interest in how the results could shape the stock’s trajectory.
While optimism appears to dominate, there are also voices on X expressing caution, pointing to recent stock price declines as a potential warning sign. Some have noted the importance of looking at broader market trends and the company’s performance in pharmaceutical distribution for a clearer picture. This mix of perspectives keeps the dialogue dynamic as the earnings date approaches.
Note: This discussion summary was generated from an AI condensation of post data.
Cardinal Health Congressional Stock Trading
Members of Congress have traded $CAH stock 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CAH stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 3 times. They made 3 purchases worth up to $45,000 on 05/14, 05/05, 03/17 and 0 sales.
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 04/08.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Cardinal Health Hedge Fund Activity
We have seen 572 institutional investors add shares of Cardinal Health stock to their portfolio, and 527 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,249,241 shares (+1666.7%) to their portfolio in Q1 2025, for an estimated $309,877,932
- MILLENNIUM MANAGEMENT LLC removed 1,990,235 shares (-58.6%) from their portfolio in Q1 2025, for an estimated $274,194,675
- MARSHALL WACE, LLP removed 1,530,104 shares (-48.5%) from their portfolio in Q1 2025, for an estimated $210,802,428
- ACADIAN ASSET MANAGEMENT LLC removed 1,290,553 shares (-59.7%) from their portfolio in Q1 2025, for an estimated $177,799,486
- JPMORGAN CHASE & CO added 1,193,983 shares (+40.0%) to their portfolio in Q1 2025, for an estimated $164,495,037
- RENAISSANCE TECHNOLOGIES LLC removed 1,087,100 shares (-63.5%) from their portfolio in Q1 2025, for an estimated $149,769,767
- GAMMA INVESTING LLC removed 956,318 shares (-99.1%) from their portfolio in Q2 2025, for an estimated $160,661,424
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Cardinal Health Government Contracts
We have seen $383,936,291 of award payments to $CAH over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF AUGUST 2024: $18,081,366
- EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF JULY 2024: $17,257,823
- EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF OCTOBER 2024: $17,153,303
- EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF SEPTEMBER 2024: $14,720,823
- EXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF NOVEMBER 2024: $14,633,711
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Cardinal Health Analyst Ratings
Wall Street analysts have issued reports on $CAH in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 07/16/2025
- Evercore ISI Group issued a "Outperform" rating on 06/12/2025
- B of A Securities issued a "Buy" rating on 06/10/2025
- Wells Fargo issued a "Overweight" rating on 06/03/2025
- UBS issued a "Buy" rating on 05/02/2025
- Baird issued a "Outperform" rating on 05/02/2025
- Mizuho issued a "Outperform" rating on 03/31/2025
To track analyst ratings and price targets for Cardinal Health, check out Quiver Quantitative's $CAH forecast page.
Cardinal Health Price Targets
Multiple analysts have issued price targets for $CAH recently. We have seen 8 analysts offer price targets for $CAH in the last 6 months, with a median target of $170.0.
Here are some recent targets:
- Erin Wright from Morgan Stanley set a target price of $190.0 on 07/16/2025
- Daniel Grosslight from Citigroup set a target price of $170.0 on 06/13/2025
- Elizabeth Anderson from Evercore ISI Group set a target price of $180.0 on 06/12/2025
- Michael Cherny from B of A Securities set a target price of $170.0 on 06/10/2025
- Stephen Baxter from Wells Fargo set a target price of $179.0 on 06/03/2025
- Kevin Caliendo from UBS set a target price of $170.0 on 05/02/2025
- Eric Coldwell from Baird set a target price of $170.0 on 05/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
